tiprankstipranks
pc:mercy

Mercy BioAnalytics

Mercy BioAnalytics, Inc. is a leader in the development of extracellular vesicle-based liquid biopsies aimed at the early detection of cancer. The company’s patented Mercy Halo™ platform leverages biomarker co-localization to analyze blood-based extracellular vesicles, which carry unique cancer signatures, to identify early-stage cancers when they are most treatable. Initially focusing on ovarian and lung cancers, Mercy BioAnalytics is committed to enhancing early cancer detection to improve patient outcomes and quality of life.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$59M
Total Amount Raised$59M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$59M
Latest Funding Amount$59M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Sep 03, 2025
Series B
$59.00M

Investors

Investor Name
Funding Round

Related News and Analysis